Lethal outcome of 5‐fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation
Open Access
- 9 July 2010
- journal article
- letter
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 70 (2) , 280-283
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced ToxicityClinical Cancer Research, 2004
- Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracilEuropean Journal of Cancer, 2004
- Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.2003
- Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase geneAnnals of Oncology, 2003
- High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity.2002
- Dihydropyrimidine Dehydrogenase Enzyme Deficiency: Clinical and Genetic Assessment of Prevalence in Turkish Cancer PatientsCancer Investigation, 2002
- Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency.2001
- Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.2000
- Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicityBritish Journal of Cancer, 1999
- CLINICAL PHARMACOKINETICS OF 5-FLUOROURACIL AND ITS METABOLITES IN PLASMA, URINE, AND BILE1987